Faculty Bibliography

Cognitive neuroscience research is typically conducted in controlled laboratory environments that hold very little resemblance to science, technology, engineering, and mathematics classrooms. Fortunately, recent advances in portable electroencephalography technology now allow researchers to collect brain data from groups of students in real-world classrooms. Even though this line of research is still new, there is growing evidence that students' engagement, memory retention, and social dynamics are reflected in the brain-to-brain synchrony between students and teachers (i.e., the similarity in their brain responses). In this Essay, I will provide an overview of this emerging line of research, discuss how this approach can facilitate new collaborations between neuroscientists and discipline-based education researchers, and propose directions for future research.

Olivopontocerebellar atrophy is a rare neurodegenerative syndrome associated with 2 distinct disorders: multiple system atrophy and spinocerebellar ataxia. We present a case involving a 66-year-old man with adult-onset progressing cerebellar signs reflective of a cerebellar syndrome with no significant family history and unremarkable genetic testing for spinocerebellar ataxia. This case was found to be most consistent with sporadic olivopontocerebellar atrophy, which falls under the multiple system atrophy category. This diagnosis can be made using F-FDG PET/CT scanning and with MRI in some cases. However, in this case, relatively new PET/CT quantification and parametric imaging software was used for analysis, CortexID Suite.

Recent case-series of small size implied a pathophysiological association between coronavirus disease 2019 (COVID-19) and severe large-vessel acute ischemic stroke. Given that severe strokes are typically associated with poor prognosis and can be very efficiently treated with recanalization techniques, confirmation of this putative association is urgently warranted in a large representative patient cohort to alert stroke clinicians, and inform pre- and in-hospital acute stroke patient pathways. We pooled all consecutive patients hospitalized with laboratory-confirmed COVID-19 and acute ischemic stroke in 28 sites from 16 countries. To assess whether stroke severity and outcomes (assessed at discharge or at the latest assessment for those patients still hospitalized) in patients with acute ischemic stroke are different between patients with COVID-19 and non-COVID-19, we performed 1:1 propensity score matching analyses of our COVID-19 patients with non-COVID-19 patients registered in the Acute Stroke Registry and Analysis of Lausanne Registry between 2003 and 2019. Between January 27, 2020, and May 19, 2020, 174 patients (median age 71.2 years; 37.9% females) with COVID-19 and acute ischemic stroke were hospitalized (median of 12 patients per site). The median National Institutes of Health Stroke Scale was 10 (interquartile range [IQR], 4-18). In the 1:1 matched sample of 336 patients with COVID-19 and non-COVID-19, the median National Institutes of Health Stroke Scale was higher in patients with COVID-19 (10 [IQR, 4-18] versus 6 [IQR, 3-14]), P=0.03; (odds ratio, 1.69 [95% CI, 1.08-2.65] for higher National Institutes of Health Stroke Scale score). There were 48 (27.6%) deaths, of which 22 were attributed to COVID-19 and 26 to stroke. Among 96 survivors with available information about disability status, 49 (51%) had severe disability at discharge. In the propensity score-matched population (n=330), patients with COVID-19 had higher risk for severe disability (median mRS 4 [IQR, 2-6] versus 2 [IQR, 1-4], P<0.001) and death (odds ratio, 4.3 [95% CI, 2.22-8.30]) compared with patients without COVID-19. Our findings suggest that COVID-19 associated ischemic strokes are more severe with worse functional outcome and higher mortality than non-COVID-19 ischemic strokes.

BACKGROUND CONTEXT: MBDs are often implicated in or contribute to degenerative disc disease (DDD). Yet, there is limited long-term, postoperative outcome data on the impact of MBDs on 2-year outcomes following 2-3-level lumbar fusion for DDD. PURPOSE: To determine if DDD patients with MBDs have comparable outcomes to those without MBDs following lumbar fusion. STUDY DESIGN/SETTING: Retrospective cohort. PATIENT SAMPLE: New York State Statewide Planning and Research Cooperative System was reviewed from 2009-2013 to identify all patients with DDD who underwent short, lumbar fusion (2-3-levels) with >=2-year follow-up OUTCOME MEASURES: Two-year outcome rates (medical/surgical complications and reoperations).
METHOD(S): The New York State Statewide Planning and Research Cooperative System was reviewed from 2009-2013 to identify all patients with DDD who underwent short, lumbar fusion (2-3 levels) with >=2-year follow-up. Patients with and without MBD (vitamin D deficiency, hyperparathyroidism, osteomalacia, and rickets) were identified. Any patients with osteoporosis or other systemic/endocrine disorders affecting bone quality were excluded. Traumatic, infectious, and neoplastic surgical indications were excluded. Cohorts were compared for demographics and 2-year outcome rates (medical/surgical complications and reoperations). Logistic regression was used to identify covariates associated with medical/surgical complications and revisions.
RESULT(S): A total of 28,959 patients were included (MBD, n=380 (1.33%); no-MBD, n=28,579). MBD pts were older (56.4 vs 53.1 years) and more often female (65.5% vs 49.80%) than no-MBD pts (all p<0.001). MBD pts had longer hospital stays (4.57 days vs 4.11 days, p=0.026), but charges were similar. MBD pts incurred higher rates of wound complications (11.8% vs 6.0%), acute renal failure (11.1% vs 4.7%), pneumonia (9.2% vs 4.4%), and implant related complications (12.1% vs 7.0%); all p<0.001. Rates of pseudarthrosis, PE, pulmonary complications, and UTI were similar between groups. MBDs were associated with developing both medical complications (OR=1.55) and surgical complications (OR=1.79), both p<0.001.
CONCLUSION(S): MBD patients have an increased risk of 2-year postop comps and reoperations following short lumbar fusion for DDD compared to patients without MBD when controlling for demographics and comorbidity profile. These data underscore the importance of preoperative screening and optimization in this patient population. FDA DEVICE/DRUG STATUS: This abstract does not discuss or include any applicable devices or drugs.
Copyright

Objective: To develop a clinical score to distinguish between the parkinsonian variant of multiple system atrophy (MSA-P) and Parkinson's disease (PD).
Background(s): The differential diagnosis between MSA-P and PD is often difficult, particularly early in the disease course.
Method(s): We compared patients with probable MSA-P and with PD with a disease duration of <3 years, selected from those who were enrolled in the Natural History Study of the Synucleinopathies, an international prospective observational study. Detailed clinical neurological, and autonomic parameters were assessed at enrollment using UMSARS part I, II and IV; Schrag quality of life (QoL) scale; burden of autonomic dysfunction by COMPASS-31 scale; smell function using the UPSIT; cardiovascular autonomic function using heart rate variability during deep-breathing, analysis of the Valsalva maneuver, orthostatic stress test, plasma catecholamine levels during supine rest and after head-up tilt; and cognitive evaluation using MoCA. Positive and negative likelihood ratios (LR) were obtained for each variable assessed. Multiple iterations of a composite score based on sequential addition of variables with the highest diagnostic accuracy were created by multiplying each variable's LR and applying a logarithmic function.
Result(s): Fifty-eight MSA-P and 53 PD patients had a disease duration of less than 3 years. The vast majority of patients had been diagnosed within the last 12 months (81% MSA-P and 66% PD patients). MSA-P patients were more frequently female (53% vs. 30% p<0.05) and younger at diagnosis (63+/-8 years vs. 71+/-8 years, p<0.001). A 7-item score comprising the bladder weighted subscore of the COMPASS-31, UMSARS's part 1, UPSIT, hyperreflexia, the motor subscore of Schrag's MSA quality of life scale, falls within 3 years of diagnosis, and new or increased snoring resulted in a ROC curve AUC of 0.983, with excellent 93% sensitivity and 98% specificity to distinguish early MSA-P from PD.
Conclusion(s): We propose a scale of 7 clinical items to distinguish early stage MSA-P from PD. It considers urinary function, olfactory function, corticospinal signs, performance of activities of daily living, motor symptoms burden on quality of life, frequent early falls and sleep disordered breathing. We are now prospectively validating the scale to determine its predictive value in our prodromal cohort. (Figure Presented)